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Cancer has always been one of the main problems 
of human society and is usually caused by functional 
impairment of regulatory mechanisms of cell growth 
and division, Therefore, cancer occurs when the 
mechanisms responsible for stabilizing the growth 
process of the cells are in impaired (1, 2). 
 Recognition of the source and stage of cancer has always been one of 
the Issues of interest to scientists. On the other hand, cancer is the 
second leading cause of death worldwide after cardiovascular disease. 
According to the Global Burden of Disease Cancer Report In 2015, 
there were 17.5 million cancer cases worldwide and over 8.7 million 
cancer deaths. Based on the same report, breast cancer, TBL (tracheal, 
bronchus, and lung) cancer and colorectal cancer were the most 
common incidents. From another perspective, one of the requirements 
for the treatment of different cancers is early diagnosis in the early 
stages. With the end of the human genome project, molecular 
medicine moved to a step beyond the genome called "proteomics". 
Proteomic ideas play an important role in discovering cancer 
biomarkers for early diagnosis of disease, prediction and prognosis, 
identifying new drug goals, monitoring the effectiveness of treatment 
and personal therapy. Nowadays with new developments in mass 
spectrometry and bioinformatics, new biomarkers can be identified for 
different cancers. To analyze a cancer, identifying only one biomarker 
does not provide enough information for that cancer, but paying 
attention to changes in the level of expression of various proteins is 
valuable. In this paper, effective proteins for breast, lung and 
colorectal cancers, have been identified and classified. Biomarkers 
sparse in different articles are combined using Text Mining and 
reviewing articles that introduced a cancer biomarker. In fact, by 
examining changes in the expression of proteins in the cancerous 
tissue and considering their significant changes, they are referred to as 
cancer marker candidates for early diagnosis or even prediction of 
future illness. This research offers a text mining algorithms to collect 
cancer biomarker's. 
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1) Cancer and Global Statistics 
After cardiovascular disease, cancer is the second 
leading cause of death in the world. According to 
global statistics in 2015, there were 17.5 million 
cancer cases worldwide and 8.7 million deaths. 
Between 2005 and 2015, cancer cases increased by 
33%. At the global level, the odds of developing 
cancer during a lifetime (age 0-79 years) differed 
between the sexes: they were 1 in 3 for men and 1 
in 4 for women (3). For men, the most common 
cancer globally was prostate cancer (1.6 million 
cases). After that, (TBL) and colorectal are in the 
next ranks. The most common causes of cancer 
deaths for men were TBL, liver, and stomach 
cancer with 1.21 million, 577000, and 535000 
deaths, respectively. For women in 2015, the most 
common incident cancers were breast, colorectal, 
and TBL cancer, with 2.4 million, 733000 and 
640000 respectively. These cancers were 
responsible for 46% of all incident cases among 
women. The leading causes of cancer Deaths were 
breast, TBL, and colorectal cancer,523000,517000, 
and 376000 deaths, respectively (3).  
2) 3 most common cancer in the world  
This section introduces 3 most common cancer, in 
which the statistical community consists of both 
male and female groups. 
a) Breast cancer: According to the latest published 
statistics, breast cancer is the most common cancer 
among all the people in the world. The number of 
people with this cancer was 2.44 million, the vast 
majority occurred in women, with 2.4 million 
Cases vs 44000 cases in men. It was the cause of 
death for 523000 women and 10000 men. One in 
14 women and 1 in 603 men developed breast 
cancer between birth and age79 years at the global 
level. It is the most common cancer for women in 
183 countries or territories and the most common 
cause of cancer deaths in women in 115 countries 
or territories (3).  
b) Tracheal, Bronchus, and Lung Cancer 
(TBL): In 2015, there were 2 million incident cases 
of TBL cancer and 1.7 million deaths. 1in18 men 
and 1in 45 women developing TBL cancer between 
birth and age 79 years. Tracheal, bronchus, and 
lung cancer was the cause of the most incident 
cases for men in 38 countries and the most common 
cause for cancer deaths in 113 countries or 
territories for women, TBL cancer was the most 
common cause of cancer deaths in 20countries and 
territories (3).  
C) Colon and Rectum Cancer: In2015, 
therewere1.7million incident cases of colon and 
rectum cancer, and it caused 832000deaths. The 
odds of developing colon and rectum cancer before 
age79 years at the global  level was higher for men 
than for women (1 in 28 men, 1 in 43 women). 
Colon and rectum cancer was the cancer with the 
highest incidence in 2015 for men in 6 countries. 
For women, colon and rectum cancer was the most 
common cause of cancer deaths in 5 countries (3).  
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This paper is organized as follows: In section II, 
Proteomics analysis are presented. biomarkers 
applications in cancer are presented, in section III. 
In Section IV, Text mining and it's rolls in cancer 
research are presented. Collected biomarkers Were 
shown in section V and the final part is conclusion.  
Proteomics and its role in cancer analysis 
Proteomics simply means many or groups of 
proteins. Proteomics is about understanding the 
structure and function of all proteins. Defective 
proteins are of the main causes of cancer. 
Therefore, they are important indications for cancer 
diagnosis and treatment. In addition, proteins are 
the main target for most medicines and are also a 
prior nature of designing different medicines. As a 
result, proteomics studies are highly important in 
order to recognize their role in cancer formation 
and control (4, 5). By identifying cancer-related 
proteins, they can be targeted with drugs that are 
designed by computer software, for example if a 
specific protein is involved in cancer, by knowing 
protein 3D structure, proteomics can be designed to 
counteract it effectively and prevent protein activity 
(6, 7). Since different individuals have different 
genetic data, they will have different proteins. 
Hence, one of the proteomics applications is to 
design a more specific drug for each person's 
treatment by determining the proteome of each 
individual (8, 9). Many of the experimental 
techniques used in proteomics, such as gel 
electrophoresis, liquid chromato-graphy and mass 
spectrometry (MS), have been around for several 
decades, yet it is only in the last 10–15 years that 
approaches have been developed allowing many 
proteins to be detected or quantified 
simultaneously, coming closer to “global” methods 
of proteome analysis (10). 
1) Proteomics applications in cancer: 
Proteomic based approaches are continuing to play 
a major role in studying the natural history and 
treatment of cancer. For example, proteomics can 
facilitate discovery of new molecular targets for 
therapy, biomarkers for early detection, and new 
endpoints for therapeutic efﬁcacy and toxicity (11 , 
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12). Identiﬁcation of speciﬁc and sensitive markers 
of cancer is an important public health concern. 
Currently, there are no effective screening options 
available for many cancer patients (13, 14). As 
mentioned, proteomics applications are the 
identification of biomarkers in the early diagnosis 
of diseases In this regard, we can compare this 
information with the status of cancer by examining 
changes in the isoforms and the various changes 
that occur in protein molecules (15- 17). 
2) Some limitations on the use of proteomics in 
diagnosis: 
To use proteomics technique, a lot of protein is 
needed (18). Low protein amount is an unreliable 
source for electrophoresis, in addition, healthy 
tissues and tumors are a mixture of different cells. 
To find biomarkers and research in this field, there 
is a need for pure samples to achieve reliable 
results. 
Biomarkers:  
Over recent years lots of attention has been paid to 
the role of biomarkers in the diagnosis of cancer in 
clinical studies (19). Biomarkers are important tools 
for tracking and studying cancer. The use of 
methods such as proteomics can help for the early 
diagnosis of cancer and also identification of 
protein biomarkers (20). This process will be 
considered as a fundamental way to treatment of 
cancer. Today, with advances in proteomics, 
biomarkers can be identified in various cancers, as 
well as the design and function of proteins. The 
advancement of proteomics and genomics has led 
to the identification of a wide range of clinically 
valuable biomarkers. Biomarkers' cognition is 
helpful in determining the (stage) of the disease and 
its specific treatment (21). Biomarkers are really 
important in timely diagnosis of cancer, the 
progression of disease, effective treatment by 
www.thecancerpress.com 
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employing the most effective techniques and also as 
a measurable factor between human populations 
(22, 23). In fact, mutation of genes and changes that 
occur in the transcription and translation of proteins 
can also be defined as cancer biomarkers. Even 
changes in serum proteins with the cancer process 
can be described as biomarkers of that cancer (24, 
25). To analyze a cancer, identifying only one 
biomarker does not provide enough information for 
that cancer, but paying attention to changes in the 
level of expression of various proteins is valuable 
(20, 26, 27). One of the methods employed in the 
field of proteomic biomarkers is the two-
dimensional electrophoresis and mass 
spectrometry. Although spectrometry is an ideal 
method for identifying biomarkers, But additional 
testing, along with electrophoresis, may also be 
helpful to verify the performance of mass 
spectrometry, including tests (LCM, Protein Arrays, 
Antibody Arrays and High density) (28, 11). By 
2006, only 12 different types of biomarkers have 
been approved by the World Organization (FDA), 
The use of other techniques to determine the correct 
biomarkers from the protein of healthy, cancerous 
and malignant cells is necessary. 
Here in, we discuss three major technologies 
presently available in proteome analysis. First the 
separation of protein mixtures by 2-DE, which is 
the only technique currently available that can 
reveal hundreds of proteins at a time. Second, 
characterization of every single protein for which 
mass spectrometric (MS) technique is the 
methodology of choice in this regard. Third, 
identiﬁcation of the proteins or polypeptides by MS 
followed by database searching using numerous 
computational algorithms is nowadays becoming 
routinely accessible .Mass spectrometry plays a 
fundamental role in the majority of protein 
identification pipelines used in proteomics. 
Individual proteins can typically be “identified” 
either by a single stage of mass spectrometry, called 
peptide mass fingerprinting (PMF), or by two 
stages, called tandem MS or MS/MS. If a single 
stage is used, a protein is digested (for example 
with trypsin) and the pattern of peptide masses  
(PMF) is compared with a theoretical digest of 
database sequences to make an identification (13, 
10).  
Text mining 
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Text mining, also referred to as text data mining, 
roughly equivalent to text analytics, is the process of 
deriving high-quality information from text. High-
quality information is typically derived through the 
devising of patterns and trends through means such 
as statistical pattern learning. Typical text mining 
tasks include text categorization, text clustering, 
concept/entity extraction, production of granular 
taxonomies, sentiment analysis, document 
summarization, and entity relation modeling. text 
mining seeks to extract useful information from non-
structured text data by detecting and displaying 
patterns. In other words, text mining is a way of 
extracting knowledge from texts. The discovery of 
new and previously unknown information is based 
on the automatic extraction of information from 
various sources of writing. Text analysis involves 
information retrieval, lexical analysis to study word 
frequency distributions, pattern recognition, tagging/
annotation, information extraction, data mining 
techniques including link and association analysis, 
visualization, and predictive analytics. The 
overarching goal is, essentially, to turn text into data 
for analysis, via application of natural language 
processing (NLP) and analytical methods. A range of 
text mining applications in the biomedical literature 
has been describe (29).One online text mining 
application in the biomedical literature is Pub Gene 
that combines biomedical text mining with network 
visualization as an Internet service (30, 31). Go 
PubMed is a knowledge-based search engine for 
biomedical texts. unstructured biomedical text is of 
great value for cancer diagnostics, treatment, and 
prevention. The immense body and rapid growth of 
biomedical text on cancer has led to the appearance 
of a large number of text mining techniques aimed at 
extracting novel knowledge from scientific text. 
Biomedical text mining on cancer research is 
computationally automatic and high-throughput in 
nature. However, it is error-prone due to the 
complexity of natural language processing (32). 
1) Text mining in cancer research: Many studies 
have been done on text mining in cancer research. 
We have reviewed the important research issues 
related to text mining in the biomedical field. Hui Li 
and Chunmei Liu (33) identified biomarkers using 
Text mining. In particular, DNA methylation is one 
of the hottest topics used for early diagnosis and 
treatment of cancer (34, 35). Different databases 
Including Pub Meth (36) and MeInfoText (32, 33) 
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have been developed for DNA methylation .Pub 
Meth (34) is a cancer methylation database with 
text mining tools and expert annotations. 
Associations among genes, methylation, and 
cancers in MeInfoText (34, 35) are extracted from a 
large body of biomedical literature. As a complex 
disease, cancer is related to a large number of genes 
and proteins. Biomedical researchers are interested 
in mining cancer-related genes and proteins from 
the literature to study cancer diagnostics, treatment, 
and prevention. Deng et al, (37) employed a text 
mining approach to identify prostate cancer-related 
genes as candidate genes and they used the OMIM 
(Online Mendelian Inheritance in Man) database to 
verify them.  Natarajan et al, (38) also built gene–
gene interaction networks for 72 genes using a text 
mining approach. Krallinger et al. implemented two 
cancer-related text mining applications (39). These 
two methods include 1-extraction of human gene 
mutations for predefined types of cancer from 
literatures and 2-breast cancer categorization and 
text-based breast cancer gene ranking. Korhonen et 
al, (40) applied biomedical text mining technology 
to cancer risk assessment. They extracted evidence 
from the literature as features and developed 
several classes for risk levels of the causes of 
cancer, from which researchers can acquire the risk 
levels. Guo et al, (41) developed classifiers for the 
automatic identification of schemes from abstracts 
to help cancer risk assessment to facilitate the study 
of cancer and other potential factors. Ben Abacha et 
al, (42) used a supervised machine learning 
approach to extract the relationships among 
medical problems, treatments, and tests. Lee et al, 
(43) developed a text mining-based system to 
discover the relationships among cancer and 
potential factors.  
They mined relationships among diseases and 
potential factors in clinical medical records using 
self-organizing maps while they used SVM to 
evaluate them. There are several case studies in the 
context of text mining resources for cancer 
research. We introduced the general workflow of 
Mohamadzadegan and Porbadakhshan 2017. The Cancer Press, 3(4): 159-169 165 
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text mining to support cancer systems biology. We 
can see that text mining has been used widely in 
cancer research. In this study, we use the sentence 
and word search method, which is a text mining 
algorithm, to identify the biomarkers. finally, we 
collected the cancer associated biomarkers.  
Biomarker Identification: 
In this section according to numerous studies we 
have identified proteins with high potential that can 
be used in recognition process and becoming a 
biomarker. Therefore, the proteins shown in 
Table1,2,3 are a set of proteins that express their 
expression significantly different in either healthy 
or cancerous tissue. This outstanding difference in 
the potential expression levels is the key factor to 
point out biomarkers. Identifying these effective 
proteins for cancer, and then their 3-D structure, 
can play a major role in drug design and early 
diagnosis of the disease. Table1,2,3 list the 
biomarkers of breast, lung and colorectal cancer 
respectively. 
Table 1: Identified biomarker candidates in Breast cancer 
Type of cancer Protein name Condition in cancerous tissues Reference 
  ALDOA a-b; G3P a-e; KPYM a-b; PGK1 a-c; 
ENOG; S10A2; S10AB; S10AB a-b; S10AD; 
S10AG; PRS10; PRS6A; PRSA6B; PRS 7-8; 
PRSA 1-7; PSB3; PSB6; PSME1; TERA a -b; 
ANXA1 a; ANXA5; ANXA5 b; CATA a; CH60 
a-c; COF1 a; COR1A; DDAH2; ENPL ; GDIR1; 
GRP78; HSPB1 c-f; LGUL ; PRDX2 a-b; 
PRDX3; RL40 a-b SODC b; SODM a-b; TCTP; 
THIO a-b; VDAC2; 
Increase in the tumoral tissues 
  
44 
GBR7 Over-expression in tumor 45 
  
PAK4 46 
HER-2 47,48,49 
P27 Reduced expression in tumor 47,48,49 
KI-67 only expresses in growing and 
proliferating cells 
50 
BRCA1 Loss of expression is a marker of 
tumor aggressiveness 
51 
GRHL3 expression appeared to decrease 
with tumor progression 
52 
BIGH3 benign tissue had a 23-fold in-
crease in expression compared to 
the infiltrating colloid carcinoma 
53 
Serotransferrin High levels in serum of cancer-
ous 
54,55 
Isoform 1 of Gelsolin decreased in breast cancer 54,55 
vitronectin lower in 2breast cancer 54,55 
DCC decrease expression in tumor 56 
B
reast can
cer
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Table 2: Identified biomarker candidates in TBL cancer  
Type of cancer Protein name Condition in cancerous tis-
sues 
Reference 
 Tubulin  -1B; laminin B1; COTL-1; γ-actin; 
Carbonic anhydrase1; ubiquitin-conjugating 
enzyme E2 - 25K; Ubiquitin carboxyl termi-
nal esterase L1 
Up-regulated more than 2fold 
in SCLC 
57 
BCA-1; IGFBP-2; MAPK13; MMP-12; 
MMP-7; NAGK; VEGF; YES; 
Up-regulated in NSLCC serum 
and tissue 
58 
  
Cadherin-1 down-regulated in NSCLC 
serum and tissue 
58 
Catalase; Endostatin; MRC1 Up-regulated in NSCLC serum 
and down-regulated in tissue 
58 
RALA; Arf6 decreased expression in tumor 59 
SURVIVIN increase in the tumoral tissues 59 
E2F1 higher in tumor samples than in 
non-tumor lung specimens 
60 
RBBP6 ١٫۶fold higher in Lung tumors 
compared with normal lung 
tissue 
61 
P53 ٢٫٩fold lower in Lung tumors 
compared with normal lung 
tissue 
61 
HE4 High levels in serum of lung 
cancer patients 
62 
SIRT3 higher in NSCLC tissue than in 
adjacent tissue 
63 
T
B
L
 can
cer
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Conclusion 
Because the identifying only one biomarker does not provide enough information for that cancer, we tried to 
collect a significant number of biomarkers.  therefore, using intelligent techniques such as text mining, and 
we could collect biomarkers that have a protein base and have been introduced in various articles as 
biomarkers. In fact, effective proteins for breast, lung and colorectal cancers, have been identified and 
classified. By identifying several biomarkers in the patient's body, early diagnosis of cancer will be possible. 
Therefore, biomarkers play an important role in the treatment of cancer.  
